Gamma-glutamyltransferase and risk of cardiovascular mortality: A dose-response meta-analysis of prospective cohort studiesReport as inadecuate




Gamma-glutamyltransferase and risk of cardiovascular mortality: A dose-response meta-analysis of prospective cohort studies - Download this document for free, or read online. Document in PDF available to download.

Background

Serum gamma-glutamyltransferase GGT elevation likely contributes to cardiovascular CV mortality, however it has remained unknown whether a dose-response relationship exists between serum GGT and CV mortality.

Methods

We searched the PubMed, EMBASE, and Cochrane library databases for prospective cohort studies published up to October 2, 2016. Summary hazard ratios HRs with their corresponding 95% confidence intervals CIs were calculated using a fixed effects model.

Findings

Nine prospective studies, including 527,589 participants and more than 7,011 cases, were included in this meta-analysis. For the moderate, high, and highest levels of GGT, the pooled HRs of CV mortality were 1.11 95% CI = 1.04–1.19, 1.29 95% CI = 1.21–1.38 and 1.59 95% CI = 1.47–1.72, respectively all p < 0.05 as compared to the lowest levels of GGT. Additionally, the HR per incremental increase of GGT by 10 U-L was 1.10 95% CI = 1.08–1.11. Evidence of a positive relationship with nonlinear trend for GGT elevation with CV mortality in females was found P = 0.04 for nonlinearity. However, a linear model was better fit to illustrate the GGT-CV mortality among males P = 0.304 for nonlinearity.

Conclusions

These findings indicate that serum GGT activity within the reference interval is positively associated with increased risk of CV mortality in a dose-response manner.



Author: Junna Wang , Dandan Zhang , Rongzhong Huang, Xingsheng Li , Wenxiang Huang

Source: http://plos.srce.hr/



DOWNLOAD PDF




Related documents